Glutathione in cancer biology and therapy

Critical Reviews in Clinical Laboratory Sciences

Volumn 43, Issue 2, 2006, Pages 143-181

  Estrela, José M ^a,b   Ortega, Angel ^a   Obrador, Elena ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bcl 2; Cancer; Cell adhesion; Cell death; Endothelium; Glutathione; Invasion; Metastases; Mitochondria; Multidrug resistance proteins; Therapy

Indexed keywords

ABC TRANSPORTER; ACIVICIN; ADENINE NUCLEOTIDE TRANSLOCASE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BUTHIONINE SULFOXIMINE; DAUNORUBICIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; GREEN FLUORESCENT PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OBLIMERSEN; PROTEIN BCL 2; RADIOSENSITIZING AGENT; TRANSMEMBRANE CONDUCTANCE REGULATOR; VASCULAR CELL ADHESION MOLECULE 1; VERAPAMIL; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE; VOLTAGE GATED CHANNEL FORMING PROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CELL INTERACTION; CELL PROTECTION; CELL SURVIVAL; DNA DAMAGE; DRUG ACCUMULATION; DRUG POTENTIATION; ENZYME METABOLISM; EXTRACELLULAR SPACE; HUMAN; IONIZING RADIATION; LYMPHOMA; MAXIMUM TOLERATED DOSE; MELANOMA; MITOSIS INHIBITION; MYELOMA; NEUROTOXICITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FUNCTION; REVIEW; STOMACH CANCER;

ANIMALS; APOPTOSIS; BUTHIONINE SULFOXIMINE; GENES, BCL-2; GLUTATHIONE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 33744994567     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360500523878     Document Type: Review

References (248)

1. Hopkins FG, Morgan EJ. Some relations between ascorbic acid and glutathione. Biochem J 1936; 30: 1446-1462.
2. Hopkins FG, Morgan EJ. The influence of thiol-groups in the activity of dehydrogenases. Biochem J 1938; 32: 611-620.
3. Meister A. Selective modification of glutathione metabolism. Science 1983; 220: 472-477.
4. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol 1989; 257: L163-173.
5. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-519.
6. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004; 134: 489-492.
7. Conway JG, Neptun DA, Garvey LK, Popp JA. Carcinogen treatment increases glutathione hydrolysis by gamma-glutamyl transpeptidase. Carcinogenesis 1987; 8: 999-1004.
8. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 2003; 57: 145-155.
9. Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 1988; 202: 343-361.
10. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA 1995; 92: 5258-5265.
11. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65: 95-106.
12. DeGraff WG, Russo A, Mitchell JB. Glutathione depletion greatly reduces neocarzinostatin cytotoxicity in Chinese hamster V79 cells. J Biol Chem 1985; 260: 8312-8315.
13. Crook TR, Souhami RL, Whyman GD, McLean AE. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. Cancer Res 1986; 46: 5035-5038.
14. Mitchell JB, Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer Suppl 1987; 8: 96-104.
15. Bump EA, Brown JM. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmacol Ther 1990; 47: 117-136.
16. Estrela JM, Obrador E, Navarro J, Lasso De la Vega MC, Pellicer JA. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat Med 1995; 1: 84-88.
17. Calvert P, Yao KS, Hamilton TC, O'Dwyer PJ. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 1998; 111-112: 213-224.
18. Voehringer DW, Hirschberg DL, Xiao J, Lu Q, Roederer M, Lock CB, Herzenberg LA, Steinman L. Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. Proc Natl Acad Sci USA 2000; 97: 2680-2685.
19. Obrador E, Carretero J, Pellicer JA, Estrela JM. Possible mechanisms for tumour cell sensitivity to TNF-alpha and potential therapeutic applications. Curr Pharm Biotechnol 2001; 2: 119-30.
20. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22: 7512-7523.
21. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22: 7369-7375.
22. Suthanthiran M, Anderson ME, Sharma VK, Meister A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc Natl Acad Sci USA 1990; 87: 3343-3347.
23. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 1991; 51: 155-194.
24. Terradez P, Asensi M, Lasso de la Vega MC, Puertes IR, Vina J, Estrela JM. Depletion of tumour glutathione in vivo by buthionine sulphoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth. Biochem J 1993; 292: 477-483.
25. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995; 18: 775-794.
26. Paolicchi A, Dominici S, Pieri L, Maellaro E, Pompella A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol 2002; 64: 1027-1035.
27. Kwon YW, Masutani H, Nakamura H, Ishii Y, Yodoi J. Redox regulation of cell growth and cell death. Biol Chem 2003; 384: 991-996.
28. Barron ES. The importance of sulfhydryl groups in biology and medicine. Tex Rep Biol Med 1953; 11: 653-670.
29. Hirono I. Mechanism of natural and acquired resistance to methyl-bis-(beta-chlorethyl)-amine N-oxide in ascites tumors. Gann 1961; 52: 39-48.
30. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med 1999; 27: 916-921.
31. Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984; 44: 4224-4232.
32. Carretero J, Obrador E, Anasagasti MJ, Martin JJ, Vidal-Vanaclocha F, Estrela JM. Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clin Exp Metastasis 1999; 17: 567-574.
33. Carretero J, Obrador E, Esteve JM, Ortega A, Pellicer JA, Sempere FV, Estrela JM. Tumoricidal activity of endothelial cells. Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro. J Biol Chem 2001; 276: 25775-25782.
34. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 2005; 111: 127-148.
35. Estrela JM, Hernandez R, Terradez P, Asensi M, Puertes IR, Vina J. Regulation of glutathione metabolism in Ehrlich ascites tumour cells. Biochem J 1992; 286: 257-262.
36. Balendiran GK, Dabur R, Fraser D. The role of glutathione in cancer. Cell Biochem Funct 2004; 22: 343-352.
37. Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999; 27: 922-935.
38. Meister A. Methods for the selective modification of glutathione metabolism and study of glutathione transport. Methods Enzymol 1985; 113: 571-585.
39. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 1999; 13: 1169-1183.
40. Orlowski M, Meister A. The gamma-glutamyl cycle: a possible transport system for amino acids. Proc Natl Acad Sci USA 1970; 67: 1248-1255.
41. Griffith OW, Mulcahy RT. The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol 1999; 73: xii, 209-267.
42. Yan N, Meister A. Amino acid sequence of rat kidney gamma- glutamylcysteine synthetase. J Biol Chem 1990; 265: 1588-1593.
43. Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem 1993; 268: 19675-19680.
44. Tsuchiya K, Mulcahy RT, Reid LL, Disteche CM, Kavanagh TJ. Mapping of the glutamate-cysteine ligase catalytic subunit gene (GLCLC) to human chromosome 6p12 and mouse chromosome 9D-E and of the regulatory subunit gene (GLCLR) to human chromosome 1p21-p22 and mouse chromosome 3H1-3. Genomics 1995; 30: 630-632.
45. Lu SC, Ge JL. Loss of suppression of GSH synthesis at low cell density in primary cultures of rat hepatocytes. Am J Physiol 1992; 263: C1181-1189.
46. Lu SC. Regulation of hepatic glutathione synthesis. Semin Liver Dis 1998; 18: 331-343.
47. Filomeni G, Aquilano K, Civitareale P, Rotilio G, Ciriolo MR. Activation of c-Jun-N-terminal kinase is required for apoptosis triggered by glutathione disulfide in neuroblastoma cells. Free Radic Biol Med 2005; 39: 345-354.
48. Oppenheimer L, Wellner VP, Griffith OW, Meister A. Glutathione synthetase. Purification from rat kidney and mapping of the substrate binding sites. J Biol Chem 1979; 254: 5184-5190.
49. Grant CM, MacIver FH, Dawes IW. Glutathione synthetase is dispensable for growth under both normal and oxidative stress conditions in the yeast Saccharomyces cerevisiae due to an accumulation of the dipeptide gamma-glutamylcysteine. Mol Biol Cell 1997; 8: 1699-1707.
50. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988; 263: 17205-17208.
51. Meister A. New aspects of glutathione biochemistry and transport - selective alteration of glutathione metabolism. Nutr Rev 1984; 42: 397-410.
52. Meister A, Anderson ME, Hwang O. Intracellular cysteine and glutathione delivery systems. J Am Coll Nutr 1986; 5: 137-151.
53. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-760.
54. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta 2003; 333: 19-39.
55. Yuan ZM, Smith PB, Brundrett RB, Colvin M, Fenselau C. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab Dispos 1991; 19: 625-629.
56. Donati YR, Slosman DO, Polla BS. Oxidative injury and the heat shock response. Biochem Pharmacol 1990; 40: 2571-2577.
57. Navarro J, Obrador E, Pellicer JA, Aseni M, Vina J, Estrela JM. Blood glutathione as an index of radiation-induced oxidative stress in mice and humans. Free Radic Biol Med 1997; 22: 1203-1209.
58. Ookhtens M, Kaplowitz N. Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. Semin Liver Dis 1998; 18: 313-329.
59. Hall AG. Glutathione and the regulation of cell death. Adv Exp Med Biol 1999; 457: 199-203.
60. Chai YC, Ashraf SS, Rokutan K, Johnston RB, Jr., Thomas JA. S-thiolation of individual human neutrophil proteins including actin by stimulation of the respiratory burst: evidence against a role for glutathione disulfide. Arch Biochem Biophys 1994; 310: 273-281.
61. Lu SC. Regulation of glutathione synthesis. Curr Top Cell Regul 2000; 36: 95-116.
62. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002; 18: 872-879.
63. Lei XG. In vivo antioxidant role of glutathione peroxidase: evidence from knockout mice. Methods Enzymol 2002; 347: 213-225.
64. Arrigo AP. Gene expression and the thiol redox state. Free Radic Biol Med 1999; 27: 936-944.
65. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999; 31: 273-300.
66. Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Ann NY Acad Sci 2002; 973: 488-504.
67. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10: 709-720.
68. Akerboom TP, Sies H. Transport of glutathione, glutathione disulfide, and glutathione conjugates across the hepatocyte plasma membrane. Methods Enzymol 1989; 173: 523-534.
69. Armstrong RN. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 1997; 10: 2-18.
70. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45: 51-88.
71. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S. Polymorphism of glutathione S-transferase Omega gene and risk of cancer. Cancer Lett 2005; June 28 (E. Pub).
72. Turella P, Cerella C, Filomeni G, Bullo A, De Maria F, Ghibelli L, Ciriolo MR, Cianfriglia M, Mattei M, Federici G, Ricci G, Caccuri AM. Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res 2005; 65: 3751-3761.
73. Ye Z, Song H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. Eur J Cancer 2005; 41: 980-989.
74. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319: 1557-1562.
75. Kretz-Remy C, Arrigo AP. Gene expression and thiol redox state. Methods Enzymol 2002; 348: 200-215.
76. Klatt P, Lamas S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 2000; 267: 4928-4944.
77. Higuchi Y. Glutathione depletion-induced chromosomal DNA fragmentation associated with apoptosis and necrosis. J Cell Mol Med 2004; 8: 455-464.
78. Salinas AE, Wong MG. Glutathione S-transferases - a review. Curr Med Chem 1999; 6: 279-309.
79. Aliya S, Reddanna P, Thyagaraju K. Does glutathione S-transferase Pi (GST-Pi) a marker protein for cancer? Mol Cell Biochem 2003; 253: 319-327.
80. Higashi K, Hiai H, Higashi T, Muramatsu M. Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle. Cancer Lett 2004; 209: 155-163.
81. Ricci G, De Maria F, Antonini G, Turella P, Bullo A, Stella L, Filomeni G, Federici G, Caccuri AM. 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem 2005; 280: 26397-26405.
82. Liu H, Wang H, Shenvi S, Hagen TM, Liu RM. Glutathione metabolism during aging and in Alzheimer disease. Ann NY Acad Sci 2004; 1019: 346-349.
83. Meredith MJ, Reed DJ. Status of the mitochondrial pool of glutathione in the isolated hepatocyte. J Biol Chem 1982; 257: 3747-3753.
84. Hwang C, Sinskey AJ, Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 1992; 257: 1496-1502.
85. Griffith OW, Meister A. Origin and turnover of mitochondrial glutathione. Proc Natl Acad Sci USA 1985; 82: 4668-4672.
86. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M, Ardite E, Morales A. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997; 273: G7-17.
87. Carretero J, Obrador E, Pellicer JA, Pascual A, Estrela JM. Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Radic Biol Med 2000; 29: 913-923.
88. Ortega AL, Carretero J, Obrador E, Gambini J, Asensi M, Rodilla V, Estrela JM. Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium. J Biol Chem 2003; 278: 13888-13897.
89. Estrela JM, Ortega AL, Carretero J. A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria? Hepatology 2004; 39: 570-571; author reply 571.
90. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998; 60: 619-642.
91. Hall AG. Review: The role of glutathione in the regulation of apoptosis. Em J Clin Invest 1999; 29: 238-245.
92. Bass R, Ruddock LW, Klappa P, Freedman RB. A major fraction of ndoplasmic reticulum-located glutathione is present as mixed disulfides with protein. J Biol Chem 2004; 279: 5257-5262.
93. Hwang C, Lodish HF, Sinskey AJ. Measurement of glutathione redox state in cytosol and secretory pathway of cultured cells. Methods Enzymol 1995; 251: 212-221.
94. Banhegyi G, Lusini L, Puskas F, Rossi R, Fulceri R, Braun L, Mile V, di Simplicio P, Mandl J, Benedetti A. Preferential transport of glutathione versus glutathione disulfide in rat liver microsomal vesicles. J Biol Chem 1999; 274: 12213-12216.
95. Csala M, Fulceri R, Mandl J, Benedetti A, Banhegyi G. Glutathione transport in the endo/sarcoplasmic reticulum. Biofactors 2003; 17: 27-35.
96. D'Alessio M, Cerella C, Amici C, Pesce C, Coppola S, Fanelli C, De Nicola M, Cristofanon S, Clavarino G, Bergamaschi A, Magrini A, Gualandi G, Ghibelli L. Glutathione depletion upregulates Bcl-2 in BSO-resistant cells. FASEB J 2004; 18: 1609-1611.
97. Voehringer DW, McConkey DJ, McDonnell TJ, Brisbay S, Meyn RE. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci USA 1998; 95: 2956-2960.
98. Navarro J, Obrador E, Carretero J, Petschen I, Avino J, Perez P, Estrela JM. Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med 1999; 26: 410-418.
99. Ookhtens M, Mittur AV, Erhart NA. Changes in plasma glutathione concentrations, turnover, and disposal in developing rats. Am J Physiol 1994; 266: R979-988.
100. Ballatori N, Rebbeor JF. Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione. Semin Liver Dis 1998; 18: 377-387.
101. Anderson ME, Meister A. Dynamic state of glutathione in blood plasma. J Biol Chem 1980; 255: 9530-9533.
102. Laperche Y, Bulle F, Aissani T, Chobert MN, Aggerbeck M, Hanoune J, Guellaen G. Molecular cloning and nucleotide sequence of rat kidney gamma-glutamyl transpeptidase cDNA. Proc Natl Acad Sci USA 1986; 83: 937-941.
103. Hanigan MH. Expression of gamma-glutamyl transpeptidase provides tumor cells with a selective growth advantage at physiologic concentrations of cyst(e)ine. Carcinogenesis 1995; 16: 181-185.
104. O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Em J Cancer 1996; 32A: 967-978.
105. van der Kolk DM, Vellenga E, Muller M, de Vries EG. Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia. Adv Exp Med Biol 1999; 457: 187-198.
106. Obrador E, Carretero J, Ortega A, Medina I, Rodilla V, Pellicer JA, Estrela JM. gamma-Glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 2002; 35: 74-81.
107. Ortega A, Ferrer P, Carretero J, Obrador E, Asensi M, Pellicer JA, Estrela JM. Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium. J Biol Chem 2003; 278: 39591-39599.
108. Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, Carretero J, Estrela JM. Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem 2005; 280: 6950-6959.
109. Hochwald SN, Harrison LE, Rose DM, Anderson M, Burt ME. gamma-Glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J Natl Cancer Inst 1996; 88: 193-197.
110. Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated pro teins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003; 17: 103-114.
111. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995; 92: 7690-7694.
112. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
113. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
114. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett 2003; 90: 103-122.
115. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
116. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995; 11: 199-210.
117. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science 1989; 244: 207-211.
118. Stanbridge EJ. Identifying tumor suppressor genes in human colorectal cancer. Science 1990; 247: 12-13.
119. Pitot HC, Goldsworthy T, Moran S. The natural history of carcinogenesis: implications of experimental carcinogenesis in the genesis of human cancer. J Supramol Struct Cell Biochem 1981; 17: 133-146.
120. Schulte-Hermann R, Grasl-Kraupp B, Bursch W. Tumor development and apoptosis. Int Arch Allergy Immunol 1994; 105: 363-367.
121. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004; 44: 239-267.
122. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, Husain SA. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000; 59: 163-170.
123. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003; 34: 955-968.
124. Sander CS, Chang H, Hamm F, Elsner P, Thiele JJ. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol 2004; 43: 326-335.
125. Ananthaswamy HN, Price JE, Goldberg LH, Bales ES. Detection and identification of activated oncogenes in human skin cancers occurring on sun-exposed body sites. Cancer Res 1988; 48: 3341-3346.
126. Suarez HG, Daya-Grosjean L, Schlaifer D, Nardeux P, Renault G, Bos JL, Sarasin A. Activated oncogenes in human skin tumors from a repair-deficient syndrome, xeroderma pigmentosum. Cancer Res 1989; 49: 1223-1228.
127. Ohshima H. Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis. Toxicol Lett 2003; 140-141: 99-104.
128. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003; 417: 3-11.
129. Aw TY. Intestinal glutathione: determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility. Toxicol Appl Pharmacol 2005; 204: 320-328.
130. Sadani GR, Nadkarni GD. Role of tissue antioxidant defence in thyroid cancers. Cancer Lett 1996; 109: 231-235.
131. Pendyala L, Velagapudi S, Toth K, Zdanowicz J, Glaves D, Slocum H, Perez R, Huben R, Creaven PJ, Raghavan D. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 1997; 3: 793-798.
132. Honda T, Coppola S, Ghibelli L, Cho SH, Kagawa S, Spurgers KB, Brisbay SM, Roth JA, Meyn RE, Fang B, McDonnell TJ. GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. Cancer Gene Ther 2004; 11: 249-255.
133. Berger SJ, Gosky D, Zborowska E, Willson JK, Berger NA. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Cancer Res 1994; 54: 4077-4083.
134. Perry RR, Mazetta JA, Levin M, Barranco SC. Glutathione levels and variability in breast tumors and normal tissue. Cancer 1993; 72: 783-787.
135. Nkabyo YS, Ziegler TR, Gu LH, Watson WH, Jones DP. Glutathione and thioredoxin redox during differentiation in human colon epithelial (Caco-2) cells. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1352-1359.
136. Moran LK, Gutteridge JM, Quinlan GJ. Thiols in cellular redox signalling and control. Curr Med Chem 2001; 8: 763-772.
137. Morel Y, Barouki R. Repression of gene expression by oxidative stress. Biochem J 1999; 342: 481-496.
138. Guyton KZ, Xu Q, Holbrook NJ. Induction of the mammalian stress response gene GADD153 by oxidative stress: role of AP-1 element. Biochem J 1996; 314: 547-554.
139. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem 1996; 271: 13422-13429.
140. Nikitovic D, Holmgren A, Spyrou G. Inhibition of AP-1 DNA binding by nitric oxide involving conserved cysteine residues in Jun and Fos. Biochem Biophys Res Commun 1998; 242: 109-112.
141. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997; 94: 3633-3638.
142. Martensson J, Lai JC, Meister A. High-affinity transport of glutathione is part of a multicomponent system essential for mitochondrial function. Proc Natl Acad Sci USA 1990; 87: 7185-7189.
143. Briviba K, Fraser G, Sies H, Ketterer B. Distribution of the monochlorobimane-glutathione conjugate between nucleus and cytosol in isolated hepatocytes. Biochem J 1993; 294: 631-633.
144. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci USA 2002; 99: 9745-9749.
145. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046-1049.
146. Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 1995; 15: 3892-3903.
147. Wu HH, Momand J. Pyrrolidine dithiocarbamate prevents p53 activation and promotes p53 cysteine residue oxidation. J Biol Chem 1998; 273: 18898-18905.
148. Lee JM. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. Oncogene 1998; 17: 1653-1662.
149. Moraes EC, Keyse SM, Pidoux M, Tyrrell RM. The spectrum of mutations generated by passage of a hydrogen peroxide damaged shuttle vector plasmid through a mammalian host. Nucleic Acids Res 1989; 17: 8301-8312.
150. Moraes EC, Keyse SM, Tyrrell RM. Mutagenesis by hydrogen peroxide treatment of mammalian cells: a molecular analysis. Carcinogenesis 1990; 11: 283-293.
151. Guyton KZ, Kensler TW. Oxidative mechanisms in carcinogenesis. Br Med Bull 1993; 49: 523-544.
152. Kosower NS, Kosower EM. The glutathione status of cells. Int Rev Cytol 1978; 54: 109-160.
153. Ochoa S. Regulation of protein synthesis initiation in eucaryotes. Arch Biochem Biophys 1983; 223: 325-349.
154. Dethmers JK, Meister A. Glutathione export by human lymphoid cells: depletion of glutathione by inhibition of its synthesis decreases export and increases sensitivity to irradiation. Proc Natl Acad Sci USA 1981; 78: 7492-7496.
155. Kang YJ, Enger MD. Glutathione content and growth in A549 human lung carcinoma cells. Exp Cell Res 1990; 187: 177-179.
156. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-665.
157. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970; 45: 773-782.
158. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes memorial award lecture. Cancer Res 1990; 50: 6130-6138.
159. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990; 54: 159-211.
160. Li LM, Nicolson GL, Fidler IJ. Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells. Cancer Res 1991; 51: 245-254.
161. Bayon LG, Izquierdo MA, Sirovich I, van Rooijen N, Beelen RH, Meijer S. Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver. Hepatology 1996; 23: 1224-1231.
162. Anasagasti MJ, Alvarez A, Martin JJ, Mendoza L, Vidal-Vanaclocha F. Sinusoidal endothelium release of hydrogen peroxide enhances very late antigen-4-mediated melanoma cell adherence and tumor cytotoxicity during interleukin-1 promotion of hepatic melanoma metastasis in mice. Hepatology 1997; 25: 840-846.
163. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000; 190: 310-329.
164. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973; 242: 148-149.
165. Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 1976; 57: 1199-1202.
166. Mendoza L, Olaso E, Anasagasti MJ, Fuentes AM, Vidal-Vanaclocha F. Mannose receptor-mediated endothelial cell activation contributes to B16 melanoma cell adhesion and metastasis in liver. J Cell Physiol 1998; 174: 322-330.
167. Garofalo A, Chirivi RG, Foglieni C, Pigott R, Mortarini R, Martin-Padura I, Anichini A, Gearing AJ, Sanchez-Madrid F, Dejana E, et al. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res 1995; 55: 414-419.
168. Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol 1986; 137: 3295-3298.
169. McCloskey TW, Todaro JA, Laskin DL. Lipopolysaccharide treatment of rats alters antigen expression and oxidative metabolism in hepatic macrophages and endothelial cells. Hepatology 1992; 16: 191-203.
170. Anasagasti MJ, Alvarez A, Avivi C, Vidal-Vanaclocha F. Interleukin-1-mediated H2O2 production by hepatic sinusoidal endothelium in response to B16 melanoma cell adhesion. J Cell Physiol 1996; 167: 314-323.
171. Sellak H, Franzini E, Hakim J, Pasquier C. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 1994; 83: 2669-2677.
172. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are egulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866-1874.
173. Wang HH, McIntosh AR, Hasinoff BB, Rector ES, Ahmed N, Nance DM, Orr FW. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res 2000; 60: 5862-5869.
174. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998; 19: 711-721.
175. Nishikawa M, Sato EF, Kuroki T, Utsumi K, Inoue M. Macrophage-derived nitric oxide induces apoptosis of rat hepatoma cells in vivo. Hepatology 1998; 28: 1474-1480.
176. Melino G, Bernassola F, Knight RA, Corasaniti MT, Nistico G, Finazzi-Agro A. S-nitrosylation regulates apoptosis. Nature 1997; 388: 432-433.
177. Pacelli R, Wink DA, Cook JA, Krishna MC, DeGraff W, Friedman N, Tsokos M, Samuni A, Mitchell JB. Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J Exp Med 1995; 182: 1469-1479.
178. Ioannidis I, de Groot H. Cytotoxicity of nitric oxide in Fu5 rat hepatoma cells: evidence for co-operative action with hydrogen peroxide. Biochem J 1993; 296: 341-345.
179. Jessup JM, Battle P, Waller H, Edmiston KH, Stolz DB, Watkins SC, Locker J, Skena K. Reactive nitrogen and oxygen radicals formed during hepatic ischemia-reperfusion kill weakly metastatic colorectal cancer cells. Cancer Res 1999; 59: 1825-1829.
180. Anasagasti MJ, Martin JJ, Mendoza L, Obrador E, Estrela JM, McCuskey RS, Vidal-Vanaclocha F. Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 1998; 27: 1249-1256.
181. Farias-Eisner R, Chaudhuri G, Aeberhard E, Fukuto JM. The chemistry and tumoricidal activity of nitric oxide/hydrogen peroxide and the implications to cell resistance/susceptibility. J Biol Chem 1996; 271: 6144-6151.
182. Chiang KT, Switzer CH, Akali KO, Fukuto JM. The role of oxygen and reduced oxygen species in nitric oxide-mediated cytotoxicity: studies in the yeast Saccharomyces cerevisiae model system. Toxicol Appl Pharmacol 2000; 167: 30-36.
183. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 1993; 90: 9813-9817.
184. Gupta MP, Evanoff V, Hart CM. Nitric oxide attenuates hydrogen peroxide-mediated injury to porcine pulmonary artery endothelial cells. Am J Physiol 1997; 272: L1133-1141.
185. Davies KJ. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 1999; 48: 41-47.
186. Han J, Stamler JS, Li H, Griffith OW. Molecular biology of nitric oxide synthases. In Stamler JS, Gross SS, Moncada S, Higgs EA, Eds. The Biology of Nitric Oxide. Pp 84-93. London: Portland Press, 1995.
187. Moellering D, McAndrew J, Patel RP, Cornwell T, Lincoln T, Cao X, Messina JL, Forman HJ, Jo H, Darley-Usmar VM. Nitric oxide-dependent induction of glutathione synthesis through increased expression of gamma-glutamylcysteine synthetase. Arch Biochem Biophys 1998; 358: 74-82.
188. Obrador E, Carretero J, Esteve JM, Pellicer JA, Pascual A, Petschen I, Estrela JM. Glutamine potentiates TNF-alpha-induced tumor cytotoxicity. Free Radic Biol Med 2001; 31: 642-650.
189. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92: 1042-1053.
190. Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R, Zhivotovsky B. Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene 2002; 21: 65-77.
191. Arai M, Imai H, Koumura T, Yoshida M, Emoto K, Umeda M, Chiba N, Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells. J Biol Chem 1999; 274: 4924-4933.
192. Marchetti P, Decaudin D, Macho A, Zamzami N, Hirsch T, Susin SA, Kroemer G. Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. Eur J Immunol 1997; 27: 289-296.
193. Zheng M, Aslund F, Storz G. Activation of the OxyR transcription factor by reversible disulfide bond formation. Science 1998; 279: 1718-1721.
194. Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med 1996; 21: 335-348.
195. Huang ZZ, Chen C, Zeng Z, Yang H, Oh J, Chen L, Lu SC. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. FASEB J 2001; 15: 19-21.
196. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000; 28: 1387-1404.
197. Lu SC, Kuhlenkamp J, Garcia-Ruiz C, Kaplowitz N. Hormone-mediated down-regulation of hepatic glutathione synthesis in the rat. J Clin Invest 1991; 88: 260-269.
198. Sun WM, Huang ZZ, Lu SC. Regulation of gamma-glutamylcysteine synthetase by protein phos-phorylation. Biochem J 1996; 320 (Pt 1): 321-328.
199. Datta R, Hallahan DE, Kharbanda SM, Rubin E, Sherman ML, Huberman E, Weichselbaum RR, Kufe DW. Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. Biochemistry 1992; 31: 8300-8306.
200. Lafrenie R, Shaughnessy SG, Orr FW. Cancer cell interactions with injured or activated endothelium. Cancer Metastasis Rev 1992; 11: 377-388.
201. Marshall HE, Merchant K, Stamler JS. Nitrosation and oxidation in the regulation of gene expression. FASEB J 2000; 14: 1889-1900.
202. Schadendorf D, Jurgovsky K, Kohlmus CM, Czarnetzki BM. Glutathione and related enzymes in tumor progression and metastases of human melanoma. J Invest Dermatol 1995; 105: 109-112.
203. Revesz L, Edgren MR, Wainson AA. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo. Int J Radiat Oncol Biol Phys 1994; 29: 403-406.
204. Thrall BD, Meadows GG. Induction of glutathione content in murine melanocytes after transformation with c-H-ras oncogene. Carcinogenesis 1991; 12: 1319-1323.
205. Eskenazi AE, Pinkas J, Whitin JC, Arguello F, Cohen HJ, Frantz CN. Role of antioxidant enzymes in the induction of increased experimental metastasis by hydroxyurea. J Natl Cancer Inst 1993; 85: 711-721.
206. Sies H, Graf P. Hepatic thiol and glutathione efflux under the influence of vasopressin, phenylephrine and adrenaline. Biochem J 1985; 2: 545-549.
207. Palomares T, Alonso-Varona A, Alvarez A, Castro B, Calle Y, Bilbao P. Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. Clin Exp Metastasis 1997; 15: 329-337.
208. Mistry P, Harrap KR. Historical aspects of glutathione and cancer chemotherapy. Pharmacol Ther 1991; 49: 125-132.
209. Reliene R, Schiestl RH. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis 2005;
210. Vahrmeijer AL, Hoetelmans RW, Mulder GJ, Schutrups J, van Vlierberghe RL, van de Velde CJ, van Dierendonck JH. Development of resistance to glutathione depletion-induced cell death in CC531 colon carcinoma cells: association with increased expression of bcl-2. Biochem Pharmacol 2000; 59: 1557-1562.
211. Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 1997; 15: 1461-1470.
212. Armstrong JS, Jones DP. Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. FASEB J 2002; 16: 1263-1265.
213. Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003; 63: 312-318.
214. Baliga BC, Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 2002; 20: 63-74.
215. Takaoka A, Adachi M, Okuda H, Sato S, Yawata A, Hinoda Y, Takayama S, Reed JC, Imai K. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 1997; 14: 2971-2977.
216. Owen-Schaub LB, van Golen KL, Hill LL, Price JE. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998; 188: 1717-1723.
217. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
218. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al-Mehdi AB, Bernhard EJ, Muschel RJ. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001; 61: 333-338.
219. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-592.
220. Hickman JA. Apoptosis and tumourigenesis. Curr Opin Genet Dev 2002; 12: 67-72.
221. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001; 92: 57-70.
222. Ogretmen B, Safa AR. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 1996; 67: 608-614.
223. Petrovic AS, Young RL, Hilgarth B, Ambros P, Korsmeyer SJ, Jaeger U. The Ig heavy chain 3′ end confers a posttranscriptional processing advantage to Bcl-2IgH fusion RNA in t(14;18) lymphoma. Blood 1998; 91: 3952-3961.
224. Schiavone N, Rosini P, Quattrone A, Donnini M, Lapucci A, Citti L, Bevilacqua A, Nicolin A, Capaccioli S. A conserved AU-rich element in the 3′ untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J 2000; 14: 174-184.
225. Rappa G, Lorico A, Flavell RA, Sartorelli AC. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 1997; 57: 5232-5237.
226. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in cute myeloid leukemia. Leukemia 1995; 9: 1661-1666.
227. Depeille P, Cuq P, Passagne I, Evrard A, Vian L. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer 2005; 93: 216-223.
228. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 1995; 72: 82-89.
229. Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol 1998; 275: C323-326.
230. Gadsby DC, Nairn AC. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 1999; 79(1 suppl): S77-107.
231. McDonald RA, Matthews RP, Idzerda RL, McKnight GS. Basal expression of the cystic fibrosis transmembrane conductance regulator gene is dependent on protein kinase A activity. Proc Natl Acad Sci USA 1995; 92: 7560-7564.
232. Cullen KV, Davey RA, Davey MW. Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. Biochem Pharmacol 2001; 62: 417-424.
233. Loe DW, Deeley RG, Cole SP. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 2000; 293: 530-538.
234. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-1972.
235. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993; 72: 3553-3563.
236. Stole E, Smith TK, Manning JM, Meister A. Interaction of gamma-glutamyl transpeptidase with acivicin. J Biol Chem 1994; 269: 21435-21439.
237. Dias N, Stein CA. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2002; 54: 263-269.
238. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 1999; 54: 36-46.
239. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999; 59: 4030-4034.
240. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 anti-sense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998; 78: 1035-1042.
241. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000; 6: 2492-2500.
242. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000; 6: 2891-2902.
243. Dalton WS. Overcoming the multidrug resistance phenotype. In De Vita VT Jr, Hellman S, Rosenberg SA, Eds. Cancer: Principles and Practice of Oncology. Pp 2655-2666. Philadelphia: J. B. Lippincott, 1993.
244. Hidalgo M, Rodriguez G, Kuhn JG, Brown T, Weiss G, MacGovren JP, Von Hoff DD, Rowinsky EK. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Clin Cancer Res 1998; 4: 2763-2770.
245. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
246. Meurette O, Lefeuvre-Orfila L, Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations. Clin Cancer Res 2005; 11: 3075-3083.
247. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Jr, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943-945.
248. Benlloch M, Mena S, Ferrer P, Obrador E, Asensi M, Pellicer A, Carretero J, Ortega A, Estrela JM. Bcl-2 and MnSOD antisense oligodeoxinucleotides and a glutamine enriched diet facilitate elimination of highly resistant B16 melanoma cells by TNF-α and chemotherapy. J Biol Chem 2005; November 1(E Pub).